Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0060597 |
| Name | atypical chronic myeloid leukemia, BCR-ABL1 negative |
| Definition | A myelodysplastic myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:8747 |
| Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myelodysplastic/myeloproliferative neoplasm atypical chronic myeloid leukemia, BCR-ABL1 negative |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01787487 | Phase II | Azacitidine + Ruxolitinib | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Active, not recruiting | USA | 0 |
| NCT03289910 | Phase II | Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | Active, not recruiting | USA | 0 |